Gsk (GLAXF) Non-Current Debt (2009 - 2026)

Gsk's Non-Current Debt history runs 18 years deep, the most recent figure standing at -$18.9 billion for Q1 2026.

• In Q1 2026, Non-Current Debt rose 8.96% year-over-year to -$18.9 billion; the TTM figure through Mar 2026 stood at -$18.9 billion (up 8.96% YoY), while the FY2025 annual figure was -$19.4 billion, down 203.91% from the prior year.
• Non-Current Debt was -$18.9 billion for Q1 2026 at Gsk, up from -$19.6 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.0 billion in Q4 2022 to a low of -$23.7 billion in Q2 2022.
• Historically, Non-Current Debt has averaged -$12.6 billion across 5 years, with a median of -$19.5 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Non-Current Debt soared 60.47% in 2022, then slumped 204.4% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $20.0 billion in 2022, then fell by 5.55% to $18.9 billion in 2023, then declined by 0.7% to $18.7 billion in 2024, then plunged by 204.4% to -$19.6 billion in 2025, then advanced by 3.44% to -$18.9 billion in 2026.
• The last three Non-Current Debt figures came in at -$18.9 billion (Q1 2026), -$19.6 billion (Q4 2025), and -$20.1 billion (Q3 2025), per Business Quant data.